Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy

References

• Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127(1):3–11.
   PubMed Web of Science ®Google Scholar
• Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844–1854.
   PubMed Web of Science ®Google Scholar
• Coiffier B. Acute tumor lysis syndrome – a rare complication in the treatment of solid tumors. Onkologie. 2010;33(10):498–499.
   PubMedGoogle Scholar
• Darmon M, Guichard I, Vincent F, Schlemmer B, Azoulay E. Prognostic significance of acute renal injury in acute tumor lysis syndrome. Leuk Lymphoma. 2010;51(2):221–227.
   PubMed Web of Science ®Google Scholar
• Shimada M, Johnson RJ, May WS, et al. A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome. Nephrol Dial Transplant. 2009;24(10):2960–2964.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26(16):2767–2778.
   PubMed Web of Science ®Google Scholar
• Cairo MS, Coiffier B, Reiter A, Younes A, Panel TE. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010;149(4):578–586.
   PubMed Web of Science ®Google Scholar
• Zaidi SZ, Aljurf M. Is rasburicase needed for prevention of tumor lysis syndrome during treatment of less aggressive hematolymphoid malignancies? J Clin Oncol. 2004;22(16):3430–3431.
   PubMed Web of Science ®Google Scholar
• Feusner JH, Ritchey AK, Cohn SL, Billett AL. Management of tumor lysis syndrome: need for evidence-based guidelines. J Clin Oncol. 2008;26(34):5657–5658.
   PubMed Web of Science ®Google Scholar
• Darmon M, Guichard I, Vincent F. Rasburicase and tumor lysis syndrome: lower dosage, consideration of indications, and hyperhydration. J Clin Oncol. 2011;29(3):e67–e68.
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S, Fayad LE, Fanale MA, et al. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol. 2012;23(6):1640–1645.
   PubMed Web of Science ®Google Scholar
• Feng X, Dong K, Pham D, Pence S, Inciardi J, Bhutada NS. Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis. J Clin Pharm Ther. 2013;38(4):301–308.
   PubMed Web of Science ®Google Scholar
• McBride A, Lathon SC, Boehmer L, Augustin KM, Butler SK, Westervelt P. Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome. Pharmacotherapy. 2013;33(3):295–303.
   PubMed Web of Science ®Google Scholar
• Azim HA, Bahr SA, Kamal NS, et al. One for the road! A study to assess the efficacy of single low-dose regimen of rasburicase in controlling hyperuricaemia in patients with tumour lysis syndrome due to haematological malignancies. Ecancermedicalscience. 2013;7:378.
   PubMedGoogle Scholar
• Herrington JD, Dinh BC. Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients. J Oncol Pharm Pract. February 18, 2014. [Epub ahead of print.]
   PubMed Web of Science ®Google Scholar
• Lopez-Olivo MA, Pratt G, Palla SL, Salahudeen A. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis. Am J Kidney Dis. 2013;62(3):481–492.
   PubMed Web of Science ®Google Scholar
• Cheuk DK, Chiang AK, Chan GC, Ha SY. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer. Cochrane Database Syst Rev. 2014;8:CD006945.
   Web of Science ®Google Scholar
• Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 2001;97(10):2998–3003.
   PubMed Web of Science ®Google Scholar
• Cortes J, Moore JO, Maziarz RT, et al. Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone – results of a multicenter phase III study. J Clin Oncol. 2010;28(27):4207–4213.
   PubMed Web of Science ®Google Scholar
• Galardy PJ, Hochberg J, Perkins SL, Harrison L, Goldman S, Cairo MS. Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children’s Oncology Group Report. Br J Haematol. 2013;163(3):365–372.
   PubMed Web of Science ®Google Scholar
• Ishizawa K, Ogura M, Hamaguchi M, et al. Safety and efficacy of rasburicase (SR29142) in a Japanese Phase II study. Cancer Sci. 2009;100(2):357–362.
   PubMed Web of Science ®Google Scholar
• Reeves DJ, Bestul DJ. Evaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer. Pharmacotherapy. 2008;28(6):685–690.
   PubMed Web of Science ®Google Scholar
• Rényi I, Bárdi E, Udvardi E, et al. Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin’s lymphoma. Pathol Oncol Res. 2007;13(1):57–62.
   PubMed Web of Science ®Google Scholar
• Pui CH, Relling MV, Lascombes F, et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia. 1997;11(11):1813–1816.
   PubMed Web of Science ®Google Scholar
• Tatay VS, Castilla JD, Ponce JM, Hurtado JM, Cantero E, Abril ML. [Rasburicase versus allopurinol in the treatment of hyperuricaemia in tumour lysis syndrome]. An Pediatr (Barc). 2010;72(2):103–110. Spanish.
   PubMed Web of Science ®Google Scholar
• Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109(7):2736–2743.
   PubMed Web of Science ®Google Scholar
• Ahn YH, Kang HJ, Shin HY, Ahn HS, Choi Y, Kang HG. Tumour lysis syndrome in children: experience of last decade. Hematol Oncol. 2011;29(4):196–201.
   PubMed Web of Science ®Google Scholar
• Darmon M, Vincent F, Camous L, et al. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique. Br J Haematol. 2013;162(4):489–497.
   PubMed Web of Science ®Google Scholar
• Cairo MS. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109(7):2736–2743.
   PubMed Web of Science ®Google Scholar
• Pannucci CJ, Wilkins EG. Identifying and avoiding bias in research. Plast Reconstr Surg. 2010;126(2):619–625.
   PubMed Web of Science ®Google Scholar
• Jeha S, Kantarjian H, Irwin D, et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia. 2005;19(1):34–38.
   PubMed Web of Science ®Google Scholar
• Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin’s lymphoma. Am J Med. 1993;94(2):133–139.
   PubMed Web of Science ®Google Scholar
• Kikuchi A, Kigasawa H, Tsurusawa M, et al. A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome. Int J Hematol. 2009;90(4):492–500.
   PubMed Web of Science ®Google Scholar
• Patte C, Sakiroglu C, Ansoborlo S, et al. Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Société Française d’Oncologie Pédiatrique LMB89 protocol. Ann Oncol. 2002;13(5):789–795.
   PubMed Web of Science ®Google Scholar
• Wössmann W, Schrappe M, Meyer U, Zimmermann M, Reiter A. Incidence of tumor lysis syndrome in children with advanced stage Burkitt’s lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol. 2003;82(3):160–165.
   PubMed Web of Science ®Google Scholar
• Eaddy M, Seal B, Tangirala K, Davies EH, O’Day K. Economic implications of rasburicase treatment in adult patients with tumour lysis syndrome. Appl Health Econ Health Policy. 2012;10(6):431–440.
   PubMedGoogle Scholar
• Eaddy M, Seal B, Tangirala M, Davies EH, O’Day K. Economic comparison of rasburicase and allopurinol for treatment of tumor lysis syndrome in pediatric patients. Am J Health Syst Pharm. 2010;67(24):2110–2114.
   PubMed Web of Science ®Google Scholar
• Annemans L, Moeremans K, Lamotte M, et al. Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin’s lymphoma in four European countries. Leuk Lymphoma. 2003;44(1):77–83.
   PubMed Web of Science ®Google Scholar
• Annemans L, Moeremans K, Lamotte M, et al. Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Support Care Cancer. 2003;11(4):249–257.
   PubMed Web of Science ®Google Scholar
• Malaguarnera G, Giordano M, Malaguarnera M. Rasburicase for the treatment of tumor lysis in hematological malignancies. Expert Rev Hematol. 2012;5(1):27–38.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Mounier N, Bologna S, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin’s lymphoma: results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol. 2003;21(23):4402–4406.
   PubMed Web of Science ®Google Scholar
• Bose P, Qubaiah O. A review of tumour lysis syndrome with targeted therapies and the role of rasburicase. J Clin Pharm Ther. 2011;36(3):299–326.
   PubMed Web of Science ®Google Scholar
• Mott FE, Esana A, Chakmakjian C, Herrington JD. Tumor lysis syndrome in solid tumors. Support Cancer Ther. 2005;2(3):188–191.
   PubMedGoogle Scholar
• Canet E, Cheminant M, Zafrani L, et al. Plasma uric acid response to rasburicase: early marker for acute kidney injury in tumor lysis syndrome? Leuk Lymphoma. 2014;55(10):2362–2367.
   PubMed Web of Science ®Google Scholar
• Finkel KW, Howard SC. Onco-nephrology: an invitation to a new field. J Clin Oncol. 2014;32(22):2389–2390.
   PubMed Web of Science ®Google Scholar
• Lascombes F, Sommelet D, Gebhard F. High efficacy of recombinant urate oxidase in prevention of renal failure related to tumor lysis syndrome (TLS). 1998;92(10):237B.
   Google Scholar
• Bosly A, Sonet A, Pinkerton CR, et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer. 2003;98(5):1048–1054.
   PubMed Web of Science ®Google Scholar
• Pohlreich D, Soukup P, Kouba M, al. Reduced-dose regimen of rasburicase with parallel allopurinol in the management of malignancy-associated hyperuricemia and tumor lysis syndrome. Bone Marrow Transplant. 2003;31:S223–S224.
   Web of Science ®Google Scholar
• Wang LY, Shih LY, Chang H, et al. Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies. Acta Haematol. 2006;115(1-2):35–38.
   PubMed Web of Science ®Google Scholar
• Ho VQ, Wetzstein GA, Patterson SG, Bradbury R. Abbreviated rasburicase dosing for the prevention and treatment of hyperuricemia in adults at risk for tumor lysis syndrome. Support Cancer Ther. 2006;3(3):178–182.
   PubMedGoogle Scholar
• Hutcherson DA, Gammon DC, Bhatt MS, Faneuf M. Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. Pharmacotherapy. 2006;26(2):242–247.
   PubMed Web of Science ®Google Scholar
• Llinares F, Burgos A, Fernández P, Villarrubia B, Ferrandis P, Ordovás JP. [Analysis and protocolization of rasburicase use in patients with hematologic neoplasms]. Farm Hosp. 2006;30(2):92–98.
   PubMedGoogle Scholar
• Campara M, Shord SS, Haaf CM. Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach. J Clin Pharm Ther. 2009;34(2):207–213.
   PubMed Web of Science ®Google Scholar
• Knoebel RW, Lo M, Crank CW. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome. J Oncol Pharm Pract. 2011;17(3):147–154.
   PubMedGoogle Scholar
• Vines AN, Shanholtz CB, Thompson JL. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients. Ann Pharmacother. 2010;44(10):1529–1537.
   PubMed Web of Science ®Google Scholar
• Yim B, Navaleza A, Haidau A, al e. Single 4.5mg dose of rasburicase for tumor lysis syndrome in adults. 2010;116(21):741–742.
   Google Scholar
• Trifilio SM, Pi J, Zook J, et al. Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies. Bone Marrow Transplant. 2011;46(6):800–805.
   PubMed Web of Science ®Google Scholar
• Trifilio S, Gordon L, Singhal S, et al. Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplant. 2006;37(11):997–1001.
   PubMed Web of Science ®Google Scholar
• Steel S, Coutsouvelis J, McKendrick J. Single dose rasburicase in tumor lysis: one hospital’s experience. Clin Oncol. 2008;4(1):18–20.
   Web of Science ®Google Scholar
• Chow V, Lee K. Single fixed dose versus weight-based dosing of rasburicase for the treatment of hyperuricemia associated with tumor lysis syndrome in adults with hematologic malignancies. 2009;7(5):196–197.
   Google Scholar
• McDonnell AM, Lenz KL, Frei-Lahr DA, Hayslip J, Hall PD. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults. Pharmacotherapy. 2006;26(6):806–812.
   PubMed Web of Science ®Google Scholar
• Chiang J, Chan A, Lian T, et al. Management of tumor lysis syndrome with a single fixed dose of rasburicase in Asian lymphoma patients: a case series and literature review. Asia Pac J Clin Oncol. 2011;7(4):351–356.
   PubMed Web of Science ®Google Scholar
• Giraldez M, Puto K. A single, fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults. Eur J Haematol. 2010;85(2):177–179.
   PubMed Web of Science ®Google Scholar